Literature DB >> 8907203

Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.

X Filella1, J Blade, A L Guillermo, R Molina, C Rozman, A M Ballesta.   

Abstract

The serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), soluble interleukin-2 receptor (sIL-2r), and interleukin-1alpha (IL-1alpha) were measured in 30 healthy subjects, 22 patients with monoclonal gammopathy of undetermined significance (MGUS), five patients with smoldering multiple myeloma (SMM), and 46 with multiple myeloma (MM). Serum levels of IL-6, TNF-alpha, and sIL-2r were significantly increased in patients with active MM when compared with normal controls. Furthermore, MM patients with advanced aggressive disease had significantly higher levels of IL-6, TNF-alpha, and sIL-2r than those with MM in plateau phase. In conclusion, our data support the involvement of IL-6, TNF-alpha, and sIL-2r in MM. This confirms recent in vitro studies suggesting that these cytokines may play a central role in the pathogenesis of MM. Our data also show that serum levels of TNF-alpha, sIL-2r, and, particularly, IL-6 could be useful in the clinical management of patients with MM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907203

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  20 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 2.  Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Authors:  Matthew J Pianko; Aaron D Goldberg; Alexander M Lesokhin
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

3.  Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Authors:  M Jourdan; K Tarte; E Legouffe; J Brochier; J F Rossi; B Klein
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

4.  Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Authors:  Hans D Menssen; Ulf Harnack; Ulrike Erben; Dario Neri; Burkhard Hirsch; Horst Dürkop
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-11       Impact factor: 4.553

Review 5.  Immune checkpoint blockade for hematologic malignancies: a review.

Authors:  Matthew J Pianko; Yuzhou Liu; Srishti Bagchi; Alexander M Lesokhin
Journal:  Stem Cell Investig       Date:  2017-04-19

6.  Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.

Authors:  Toyoko Hiroi; Clayton B Deming; Haige Zhao; Baranda S Hansen; Elisabeth K Arkenbout; Thomas J Myers; Michael A McDevitt; Jeffrey J Rade
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

7.  Etanercept therapy in patients with advanced primary amyloidosis.

Authors:  M A Hussein; J V Juturi; L Rybicki; S Lutton; B R Murphy; M A Karam
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

8.  Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

Authors:  Wenjie He; Amitabha Mazumder; Tuere Wilder; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-05-16       Impact factor: 5.191

9.  Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.

Authors:  G I Kirchner; A Franzke; J Buer; W Beil; M Probst-Kepper; F Wittke; K Overmann; S Lassmann; R Hoffmann; H Kirchner; A Ganser; J Atzpodien
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

10.  A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival.

Authors:  Maria Kowalska; Janina Kaminska; Malgorzata Fuksiewicz; Beata Kotowicz; Magdalena Chechlinska; Agnieszka Druzd-Sitek; Jan Walewski
Journal:  Med Oncol       Date:  2009-12-31       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.